J Korean Soc Neonatol.  2001 Nov;8(2):257-264.

Aspirin vs. Indomethacin in the Treatment of Patent Ductus Arteriosus in Very Low Birth Weight Infants

• Lee YA

Abstract

PURPOSE: To compare the effect of indomethacin to aspirin in the closure of patent ductus arteriosus (PDA) in very low birth weight (VLBW) infants with respiratory distress syndrome. To evaluates the side effects of aspirin in very low birth weight infants.
METHODS
We evaluated 25 VLBW infants treated with either indomethacin or aspirin for PDA as shown by their medical recorder. In 12 infants (mean gestational age 30.3+/-2.1 wk, mean birth weight 1232.0+/-314.3 gm) were treated with indomethacin, 0.1-0.25 mg per kilogram, every 12 hours for 3 doses. In another 13 infants (mean gestational age: 29.1+/-2.1 wk, mean birth weight: 1180.0+/-332.4 gm) aspirin was administered 10 mg per kilogram, every six hours for four doses. PDA and the degree of shunting were evaluated by echocardio-Doppler. The side effects were carefully assessed.
RESULTS
There was PDA closure in 8/12 patients from the indomethacin group (66.7%) and in 9/13 patients from the aspirin group (69.2%). Six patients were further treated with indomethacin there was and PDA closure. A decrease of uresis in the aspirin group was not observed.
Conclusions
: Aspirin has some effect in the closure of PDA in VLBW infants without a decrease of renal function.

Keyword

Very low birth weight infant; Patent ductus arteriosus; Aspirin

MeSH Terms

Aspirin*
Birth Weight
Ductus Arteriosus, Patent*
Gestational Age
Humans
Indomethacin*
Infant*
Infant, Very Low Birth Weight*
Medical Records
Aspirin
Indomethacin